Dergiler / Turkish Journal of Urology / 2022 / Cilt: 48 - Sayı: 2

The Combined Effect of Downregulated RB1 and Overexpressed lncRNA SSTRS-AS1 on Prediction Time to Castration-Resistant Prostate Cancer: Indonesian Cohort Studies

Sayfa
112–117
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Additionally, patients with International Society of Urological Pathology (ISUP) score >4 did not demonstrate this predic- tive value on time to castration-resistant prostate cancer.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Identifying the mechanism underlying the initiation and development of castration-resistant pros- tate cancer remains challenging.
📊
Temel Bulgular & Veri:This study aimed to evaluate the combined effect of downregulated RB1 and overexpressed SSTR5-AS1 as biomarkers for predicting time to castration- resistant prostate cancer.
💡
Sonuç & Katkı:Additionally, patients with International Society of Urological Pathology (ISUP) score >4 did not demonstrate this predic- tive value on time to castration-resistant prostate cancer.
🔬Tür:Araştırma Makalesi
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Identifying the mechanism underlying the initiation and development of castration-resistant pros- tate cancer remains challenging. Time to castration-resistant prostate cancer is defined by prostate-specific antigen progression and may represent a risk factor for developing immune alterations with a negative prog- nostic role in the overall survival of patients with prostate cancer. This study aimed to evaluate the combined effect of downregulated RB1 and overexpressed SSTR5-AS1 as biomarkers for predicting time to castration- resistant prostate cancer. Material and Methods: The clinical and pathological data of patients with prostate cancer were collected retrospectively. Between 2015 and 2019, a total of 36 patients who received castration were included. Expressions of mRNA of RB1 and SSTR5-AS1 from primary tumors were quantified using quantitative real- time polymerase chain reaction. Patients were divided into 2 groups: the first group consisted of patients with Rb1 expression lower than the median and expression of SSTRS5-AS1 higher than the median, and the sec- ond group consisted of all the other patients. This study was conducted in compliance with the latest Helsinki Declaration and registered on Elsevier International Standard Randomized Controlled trial number registry. Results: In this study, patients with both downregulated RB1 and overexpressed Long non-coding RNAs (lncRNA) SSTR5-AS1 showed shorter time to castration-resistant prostate cancer (mean 23.6 ± 3.3 months) compared to other groups (mean 38.3 ± 4.9 months) (log-rank test, P = .028). Conclusion: The combination of downregulation of RB1 and overexpression of SSTR5-AS1 is a strong predictor of shorter time to castration-resistant prostate cancer in the Indonesian population. Additionally, patients with International Society of Urological Pathology (ISUP) score >4 did not demonstrate this predic- tive value on time to castration-resistant prostate cancer.

🔖

Bu Makaleye Atıf Yap

SOEROHARDJO, I., ZULFİQQAR, A., WİDODO, I., HERİYANTO, D. S., ANWAR, S. L. (2022). The Combined Effect of Downregulated RB1 and Overexpressed lncRNA SSTRS-AS1 on Prediction Time to Castration-Resistant Prostate Cancer: Indonesian Cohort Studies. Turkish Journal of Urology, Cilt: 48 - Sayı: 2, 112–117. https://ajindex.com/articles/413247

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Soerohardjo I, Widodo I, Heriyanto DS, Zulfiqqar A, Anwar SL. Down-regulation of RB1 and TP53 as potential predicting biomark- ers for castration-resistant prostate cancer (CRPC): Indonesian retrospective cohort study. Ann Med Surg (Lond). 2020
  2. [CrossRef] 2. Rajput R, Sehgal A. Endocrine manipulations in cancer prostate: a review. Indian J Endocrinol Metab. 2012
  3. 16(Suppl 2):S199-S204. [CrossRef] 3. Shah H, Vaishampayan U. Therapy of advanced prostate cancer: targeting the androgen receptor axis in earlier lines of treatment. Target Oncol. 2018
  4. 13(6):679-689. [CrossRef] 4. Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021
  5. 7(1):9. [CrossRef] 5. Budaya TN, Shigeo H. Predictive factor to castrate-resistant pros- tate cancer (CRPC) after primary androgen deprivation therapy (ADT): single center experience in Indonesia. 2020
  6. Babjuk M, Burger M, Compérat EM, et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) −2019 update. Eur Urol. 2019
  7. 76(5): 639-657. [CrossRef] 7. Tian S, Lei Z, Gong Z, Sun Z, Xu D, Piao M. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review. Cancer Cell Int. 2020
  8. 20(1): 409. [CrossRef] 8. Bienz M, Saad F. Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review. BoneKEy Rep. 2015
  9. [CrossRef] 9. Ramnarine VR, Alshalalfa M, Mo F, et al. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. GigaScience. 2018
  10. 7(6):giy050. [CrossRef] 10. Ruscica M, Magni P, Steffani L, et al. Characterization and sub- cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. Mol Cell Endocrinol. 2014
  11. 382(2):860- 870. [CrossRef] 11. Qian ZR, Li T, Ter-Minassian M, et al. Association between soma- tostatin receptor expression and clinical outcomes in neuroendo- crine tumors. Pancreas. 2016
  12. 45(10):1386-1393. [CrossRef] 12. Maas M, Mayer L, Hennenlotter J, et al. Prognostic impact of somatostatin receptor expression in advanced bladder cancer. Urol Oncol. 2020
  13. 38(12):935.e17-935.e28. [CrossRef] 13. Usmani S, Orevi M, Stefanelli A, et al. Neuroendocrine differen- tiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: a narrative review. Cr